NEW TREATMENT TARGETS NATURAL TEARS FOR DRY EYES

RESTASIS^®1 is Now Approved by Health Canada for the Treatment of Dry Eye Disease

TORONTO, Nov. 25 /CNW/ - Allergan is pleased to announce that Health Canada has approved RESTASIS^® (cyclosporine) ophthalmic emulsion, 0.05% w/v for the treatment of moderate to moderately severe Dry Eye disease ("Dry Eye").  RESTASIS^® is the first prescription eye drop to target the underlying cause of chronic Dry Eye.

The prevalence of Dry Eye increases with age, affecting five to 30 per cent of the people over the age of 50, and is one of the most common reasons that people visit their eye doctor.² Dry Eye occurs when the eye fails to produce the proper quantity and/or quality of tears to keep the eye moist.² Tears act as a natural lubricant to protect against bacteria and environmental irritants such as dust, smoke, or extreme weather.³

RESTASIS^® helps increase the eye's natural ability to produce tears, which may be reduced by inflammation due to Dry Eye.^4,5

"Dry Eye can cause fluctuating and reduced vision that can affect a person ability to work, drive be self dependent and have a serious impact on their quality of life," says Dr. Bruce Jackson, Professor of Ophthalmology, University of Ottawa Eye Institute, The Ottawa Hospital.

"By increasing tear production, RESTASIS^® is the first approved drug that targets the underlying cause of Dry Eye. We know that by decreasing inflammation it will increase tear production - decreasing discomfort - and can improve the patients overall quality of life."

Symptoms of Dry Eye disease can vary in degree of severity and can include: pain, itching, irritation, light sensitivity, and a sandy or gritty sensation. If left untreated, Dry Eye can lead to more serious problems, including scarring or ulceration of the cornea and increased risk of eye infection.^2,4

"Dry Eye is more than just the symptoms, it interferes with every aspect of your life and stops you from doing the things you love," says Diane Pilon. "RESTASIS^® gave me my life back. With clear vision and being pain free - I'm driving safely, reading more comfortably, and have even gone back to skiing."

About RESTASIS^® (cyclosporine ophthalmic emulsion) 0.05%

RESTASIS^® is a safe and effective treatment for Dry Eye and is the only therapeutic eye drop demonstrated to treat the underlying cause of Dry Eye.³ In a real-world study of 3,145 patients, 83 per cent surveyed stated that they had an intention to continue using RESTASIS^® ophthalmic emulsion.⁶ Further, only five out of 293 patients discontinued use of RESTASIS^® due to burning or stinging.⁷

RESTASIS^® helps increase the eyes' natural ability to produce tears, which may be reduced by inflammation due to Dry Eye.^4,5 RESTASIS^® should be dosed at one drop per eye, twice daily.⁵

About Allergan, Inc.

Allergan is a multi-specialty health care company established 60 years ago with a commitment to uncover the best of science and develop and deliver innovative and meaningful treatments to help people reach their life's potential.  Today, we have more than 9,000 highly dedicated and talented employees, global marketing and sales capabilities with a presence in more than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals, biologics and medical devices, and state-of-the-art resources in R&D, manufacturing and safety surveillance that help millions of patients see more clearly, move more freely and express themselves more fully. From our beginnings as an eye care company to our focus today on several medical specialties, including ophthalmology, neurosciences, obesity, urologics, medical aesthetics and dermatology, Allergan is proud to celebrate 60 years of medical advances and proud to support the patients and physicians who rely on our products and the employees and communities in which we live and work. In Canada, Allergan employs more than 170 people and has a corporate head office in Markham, Ontario.

Video News Release will be available via satellite on Thursday November 25, 2010 at:

10:30 - 11:00 and again at 14:30 - 15:00 Eastern

Galaxy 17/K13
Download Freq: 11960MHz Horizontal
Audio subcarriers 5.41 left, 6.17 right

For assistance with the feed call: 1-800-565-1471

Video News Release also available via download Thursday November 25th:

Click here to access broadcast quality footage http://www.newscanada.com/mpgdownload.asp?id=nc4082  

Please contact [email protected] if you do not have your Login ID and Password.

¹ RESTASIS^® mark owned by Allergan, Inc.
² Jackson WB. Management of dysfunctional tear syndrome. Can J Ophthalmol. 2009;44(4):385-394.
³ Allergan U.S. Chronic Dry Eye Disease Overview.
⁴ Rao, SN. Topical Cyclosporine 0.05% for the Prevention of Dry Eye Disease Progression. Journal of Occular Pharmacology and Theraputics. 2010; 26(2); 157-164.
⁵ RESTASIS^® Product Monograph, August 2010.
⁶ Allergan U.S. RESTASIS® Fact Sheet.
⁷ Sall K, Stevenson, OD, Mundorf, Reis BL, and the CsA Phase 3 Study Group. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology. 2000; 107(4):631-639.

For further information: